Symbols / ALZN $1.00 -1.97% Alzamend Neuro, Inc.
ALZN Chart
About
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 3.80M |
| Enterprise Value | 1.09M | Income | -7.54M | Sales | — |
| Book/sh | 0.57 | Cash/sh | 0.71 | Dividend Yield | — |
| Payout | 0.00% | Employees | 4 | IPO | — |
| P/E | — | Forward P/E | -0.38 | PEG | — |
| P/S | — | P/B | 1.74 | P/C | — |
| EV/EBITDA | -0.16 | EV/Sales | — | Quick Ratio | 1.46 |
| Current Ratio | 1.99 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -3.67 | EPS next Y | -2.60 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-11 16:00 | ROA | -107.01% |
| ROE | -249.97% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 3.80M |
| Shs Float | 3.79M | Short Float | 6.51% | Short Ratio | 3.62 |
| Short Interest | — | 52W High | 8.82 | 52W Low | 0.98 |
| Beta | -0.05 | Avg Volume | 145.15K | Volume | 96.01K |
| Target Price | $28.00 | Recom | None | Prev Close | $1.02 |
| Price | $1.00 | Change | -1.97% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$28.00
Mean price target
2. Current target
$1.01
Latest analyst target
3. DCF / Fair value
$-17.11
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.01
Low
$28.00
High
$28.00
Mean
$28.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-22 | main | Ascendiant Capital | Buy → Buy | $28 |
| 2025-09-25 | main | Ascendiant Capital | Buy → Buy | $42 |
| 2025-08-21 | main | Ascendiant Capital | Buy → Buy | $45 |
| 2025-03-17 | main | Ascendiant Capital | Buy → Buy | $20 |
| 2024-12-16 | main | Ascendiant Capital | Buy → Buy | $32 |
| 2024-11-11 | main | Ascendiant Capital | Buy → Buy | $35 |
- ALZN Stock Price, Quote & Chart | ALZAMEND NEURO INC (NASDAQ:ALZN) - ChartMill hu, 02 Apr 2026 07
- New bipolar trial scans how lithium reaches the brain at Mass General - Stock Titan Mon, 16 Mar 2026 07
- Alzamend Neuro Receives Nasdaq Notice Over Equity Deficiency - theglobeandmail.com Sat, 21 Mar 2026 21
- EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants - finance.yahoo.com Wed, 19 Nov 2025 08
- [8-K] Alzamend Neuro, Inc. Reports Material Event - Stock Titan Fri, 20 Mar 2026 07
- Alzamend Neuro in Freefall: A 22% Plunge Shatters $1.93 as Panic Sets In - Bitget hu, 26 Mar 2026 07
- Alzamend Neuro: Will Topline Data Spark Investor Interest? - RTTNews Wed, 26 Nov 2025 08
- 12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga Fri, 27 Mar 2026 17
- symbol__ Stock Quote Price and Forecast - CNN Sun, 03 Mar 2024 15
- Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? - finance.yahoo.com Mon, 26 Jan 2026 08
- Across 26 brain regions, Alzamend’s lithium drug showed higher levels - Stock Titan hu, 26 Mar 2026 07
- Alzamend Neuro Mourns Loss of Director Andrew Woo - theglobeandmail.com Wed, 19 Nov 2025 08
- Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled - msn.com hu, 29 May 2025 07
- Alzamend Neuro announces passing of board member Andrew H. Woo - Investing.com ue, 18 Nov 2025 08
- 12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga Fri, 09 Jan 2026 08
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
4.50
-54.75%
|
9.94
-33.17%
|
14.87
+20.71%
|
12.32
|
| Research And Development |
|
1.41
-78.08%
|
6.46
-13.31%
|
7.45
+43.15%
|
5.20
|
| Selling General And Administration |
|
3.08
-11.50%
|
3.48
-53.09%
|
7.42
+4.30%
|
7.12
|
| Selling And Marketing Expense |
|
0.35
+40.42%
|
0.25
-66.69%
|
0.74
+4106.42%
|
0.02
|
| General And Administrative Expense |
|
2.73
-15.47%
|
3.24
-51.58%
|
6.68
-5.89%
|
7.10
|
| Salaries And Wages |
|
1.51
-12.99%
|
1.74
-63.97%
|
4.82
-6.64%
|
5.16
|
| Other Gand A |
|
0.96
-13.67%
|
1.12
-12.47%
|
1.28
+4.14%
|
1.23
|
| Total Expenses |
|
4.50
-54.75%
|
9.94
-33.17%
|
14.87
+20.71%
|
12.32
|
| Operating Income |
|
-4.50
+54.75%
|
-9.94
+33.17%
|
-14.87
-20.71%
|
-12.32
|
| Total Operating Income As Reported |
|
-4.50
+54.75%
|
-9.94
+33.17%
|
-14.87
-20.71%
|
-12.32
|
| EBITDA |
|
-4.45
+55.03%
|
-9.89
+33.41%
|
-14.85
-20.59%
|
-12.31
|
| Normalized EBITDA |
|
-4.45
+55.03%
|
-9.89
+33.41%
|
-14.85
-20.55%
|
-12.32
|
| Reconciled Depreciation |
|
0.05
+0.00%
|
0.05
+119.98%
|
0.02
+549.93%
|
0.00
|
| EBIT |
|
-4.50
+54.75%
|
-9.94
+33.17%
|
-14.87
-20.75%
|
-12.32
|
| Total Unusual Items |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Special Income Charges |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Other Special Charges |
|
—
|
—
|
—
|
-0.00
|
| Net Income |
|
-4.51
+54.61%
|
-9.95
+33.14%
|
-14.88
-20.35%
|
-12.36
|
| Pretax Income |
|
-4.51
+54.61%
|
-9.95
+33.14%
|
-14.88
-20.35%
|
-12.36
|
| Net Non Operating Interest Income Expense |
|
-0.02
-78.49%
|
-0.01
-31.16%
|
-0.01
+83.45%
|
-0.05
|
| Interest Expense Non Operating |
|
0.02
+78.49%
|
0.01
+31.16%
|
0.01
-83.45%
|
0.05
|
| Net Interest Income |
|
-0.02
-78.49%
|
-0.01
-31.16%
|
-0.01
+83.45%
|
-0.05
|
| Interest Expense |
|
0.02
+78.49%
|
0.01
+31.16%
|
0.01
-83.45%
|
0.05
|
| Interest Income Non Operating |
|
—
|
—
|
—
|
0.00
|
| Interest Income |
|
—
|
—
|
—
|
0.00
|
| Other Income Expense |
|
—
|
—
|
—
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-4.51
+54.61%
|
-9.95
+33.14%
|
-14.88
-20.35%
|
-12.36
|
| Net Income From Continuing Operation Net Minority Interest |
|
-4.51
+54.61%
|
-9.95
+33.14%
|
-14.88
-20.35%
|
-12.36
|
| Net Income From Continuing And Discontinued Operation |
|
-4.51
+54.61%
|
-9.95
+33.14%
|
-14.88
-20.35%
|
-12.36
|
| Net Income Continuous Operations |
|
-4.51
+54.61%
|
-9.95
+33.14%
|
-14.88
-20.35%
|
-12.36
|
| Normalized Income |
|
-4.51
+54.61%
|
-9.95
+33.14%
|
-14.88
-20.31%
|
-12.37
|
| Net Income Common Stockholders |
|
-5.11
+48.68%
|
-9.95
+33.14%
|
-14.88
-20.35%
|
-12.36
|
| Diluted EPS |
|
-11.32
+91.45%
|
-132.33
+42.19%
|
-228.90
-21.11%
|
-189.00
|
| Basic EPS |
|
-11.32
+91.45%
|
-132.33
+42.19%
|
-228.90
-21.11%
|
-189.00
|
| Basic Average Shares |
|
0.45
+499.67%
|
0.08
+15.63%
|
0.07
-1.49%
|
0.07
|
| Diluted Average Shares |
|
0.45
+499.67%
|
0.08
+15.63%
|
0.07
-1.49%
|
0.07
|
| Diluted NI Availto Com Stockholders |
|
-5.11
+48.68%
|
-9.95
+33.14%
|
-14.88
-20.35%
|
-12.36
|
| Insurance And Claims |
|
0.26
-32.05%
|
0.38
-35.02%
|
0.59
-17.77%
|
0.71
|
| Preferred Stock Dividends |
|
0.59
|
—
|
—
|
—
|
| Line Item | Trend | 2024-04-30 |
|---|---|---|
| Total Assets |
|
0.63
|
| Current Assets |
|
0.46
|
| Cash Cash Equivalents And Short Term Investments |
|
0.38
|
| Cash And Cash Equivalents |
|
0.38
|
| Cash Financial |
|
0.38
|
| Receivables |
|
—
|
| Other Receivables |
|
—
|
| Accrued Interest Receivable |
|
—
|
| Prepaid Assets |
|
0.08
|
| Current Deferred Assets |
|
—
|
| Total Non Current Assets |
|
0.18
|
| Net PPE |
|
0.18
|
| Total Liabilities Net Minority Interest |
|
3.23
|
| Current Liabilities |
|
3.23
|
| Payables And Accrued Expenses |
|
2.93
|
| Payables |
|
2.93
|
| Accounts Payable |
|
2.93
|
| Current Debt And Capital Lease Obligation |
|
0.30
|
| Current Debt |
|
0.30
|
| Other Current Borrowings |
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
| Stockholders Equity |
|
-2.59
|
| Common Stock Equity |
|
-2.59
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
0.08
|
| Ordinary Shares Number |
|
0.08
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
51.43
|
| Retained Earnings |
|
-54.02
|
| Total Equity Gross Minority Interest |
|
-2.59
|
| Total Capitalization |
|
-2.59
|
| Working Capital |
|
-2.77
|
| Invested Capital |
|
-2.29
|
| Total Debt |
|
0.30
|
| Net Tangible Assets |
|
-2.59
|
| Tangible Book Value |
|
-2.59
|
| Current Notes Payable |
|
0.30
|
| Dueto Related Parties Current |
|
—
|
| Notes Receivable |
|
—
|
| Other Equity Interest |
|
—
|
| Preferred Stock Equity |
|
—
|
| Line Item | Trend | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-6.57
+20.58%
|
-8.27
+7.32%
|
-8.92
-34.91%
|
-6.61
|
| Cash Flow From Continuing Operating Activities |
|
-6.57
+20.58%
|
-8.27
+7.32%
|
-8.92
-34.91%
|
-6.61
|
| Net Income From Continuing Operations |
|
-4.51
+54.61%
|
-9.95
+33.14%
|
-14.88
-20.35%
|
-12.36
|
| Depreciation Amortization Depletion |
|
0.05
+0.00%
|
0.05
+119.98%
|
0.02
+549.93%
|
0.00
|
| Depreciation |
|
0.05
+0.00%
|
0.05
+119.98%
|
0.02
+549.93%
|
0.00
|
| Depreciation And Amortization |
|
0.05
+0.00%
|
0.05
+119.98%
|
0.02
+549.93%
|
0.00
|
| Other Non Cash Items |
|
0.01
+1200.56%
|
0.00
|
—
|
0.01
|
| Stock Based Compensation |
|
0.33
-65.98%
|
0.96
-73.33%
|
3.58
-18.73%
|
4.41
|
| Operating Gains Losses |
|
—
|
—
|
—
|
-0.00
|
| Change In Working Capital |
|
-2.44
-463.59%
|
0.67
-71.45%
|
2.35
+77.02%
|
1.33
|
| Change In Prepaid Assets |
|
-0.15
-124.28%
|
0.62
-4.10%
|
0.64
+1.33%
|
0.63
|
| Change In Payables And Accrued Expense |
|
-2.29
-4266.49%
|
0.05
-96.78%
|
1.71
+146.15%
|
0.69
|
| Investing Cash Flow |
|
-0.30
-103.74%
|
-0.15
|
0.00
+100.00%
|
-0.11
|
| Cash Flow From Continuing Investing Activities |
|
-0.30
-103.74%
|
-0.15
|
0.00
+100.00%
|
-0.11
|
| Net PPE Purchase And Sale |
|
-0.30
-103.74%
|
-0.15
|
0.00
+100.00%
|
-0.11
|
| Purchase Of PPE |
|
-0.30
-103.74%
|
-0.15
|
0.00
+100.00%
|
-0.11
|
| Capital Expenditure |
|
-0.30
-103.74%
|
-0.15
|
—
|
-0.11
|
| Net Other Investing Changes |
|
—
|
—
|
—
|
—
|
| Financing Cash Flow |
|
10.44
+185.86%
|
3.65
+1826112.50%
|
0.00
-100.00%
|
18.85
|
| Cash Flow From Continuing Financing Activities |
|
10.44
+185.86%
|
3.65
+1826112.50%
|
0.00
-100.00%
|
18.85
|
| Net Issuance Payments Of Debt |
|
0.00
-100.00%
|
0.30
|
0.00
+100.00%
|
-0.06
|
| Issuance Of Debt |
|
0.00
-100.00%
|
0.30
|
0.00
|
0.00
|
| Repayment Of Debt |
|
—
|
—
|
0.00
+100.00%
|
-0.06
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Payments |
|
—
|
—
|
0.00
+100.00%
|
-0.06
|
| Net Long Term Debt Issuance |
|
—
|
—
|
0.00
+100.00%
|
-0.06
|
| Short Term Debt Issuance |
|
0.00
-100.00%
|
0.30
|
0.00
|
—
|
| Net Short Term Debt Issuance |
|
0.00
-100.00%
|
0.30
|
0.00
|
—
|
| Net Common Stock Issuance |
|
2.70
+115.91%
|
1.25
|
0.00
-100.00%
|
18.91
|
| Proceeds From Stock Option Exercised |
|
0.00
|
0.00
-100.00%
|
0.00
-90.91%
|
0.00
|
| Net Other Financing Charges |
|
—
|
—
|
—
|
—
|
| Changes In Cash |
|
3.57
+174.98%
|
-4.76
+46.60%
|
-8.92
-173.53%
|
12.13
|
| Beginning Cash Position |
|
0.38
-92.69%
|
5.14
-63.45%
|
14.06
+628.97%
|
1.93
|
| End Cash Position |
|
3.95
+950.04%
|
0.38
-92.69%
|
5.14
-63.45%
|
14.06
|
| Free Cash Flow |
|
-6.87
+18.40%
|
-8.42
+5.67%
|
-8.92
-32.78%
|
-6.72
|
| Common Stock Issuance |
|
2.70
+115.91%
|
1.25
|
0.00
-100.00%
|
18.91
|
| Issuance Of Capital Stock |
|
10.44
+211.42%
|
3.35
|
0.00
-100.00%
|
18.91
|
| Net Preferred Stock Issuance |
|
7.74
+268.39%
|
2.10
|
0.00
|
—
|
| Preferred Stock Issuance |
|
7.74
+268.39%
|
2.10
|
0.00
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-20 View
- 10-Q2026-03-11 View
- 8-K2026-03-06 View
- 42025-12-30 View
- 42025-12-23 View
- 10-Q2025-12-09 View
- 8-K2025-11-18 View
- 42025-10-24 View
- 8-K2025-10-14 View
- 42025-10-10 View
- 8-K2025-10-09 View
- 42025-10-08 View
- 42025-10-03 View
- 42025-09-30 View
- 42025-09-25 View
- 8-K2025-09-25 View
- 42025-09-23 View
- 42025-09-19 View
- 10-Q2025-09-10 View
- 8-K2025-08-01 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|